Literature DB >> 10084478

Eosinophilic inflammation in the airway is related to glucocorticoid reversibility in patients with pulmonary emphysema.

K Fujimoto1, K Kubo, H Yamamoto, S Yamaguchi, Y Matsuzawa.   

Abstract

STUDY
OBJECTIVES: We examined the effects of glucocorticoids on airway inflammation and its association with the reversibility of airflow obstruction in response to oral glucocorticoid administration in patients with COPD. PATIENTS: Twenty-four male patients with smoking-related stable pulmonary emphysema without alpha1-antitrypsin deficiency and nine normal healthy volunteers. MEASUREMENTS: We measured the pulmonary function, the inflammatory cells, and the levels of eosinophil cationic protein (ECP), immunoreactive neutrophil elastase-alpha1-protease inhibitor (NE-alpha1-PI) complex, and interleukin (IL)-8 in sputum induced from patients with pulmonary emphysema in its stable phase before and after treatment with 20 mg oral prednisolone per day for 2 weeks.
RESULTS: The eosinophil and neutrophil counts and the concentrations of ECP, NE-alpha1-PI complex, and IL-8 in the sputum were significantly increased at baseline. The eosinophil count at baseline was significantly correlated with the reversibility of airflow obstruction following treatment, and the treatment also significantly reduced the eosinophil numbers and ECP level in the sputum. In contrast, the increased neutrophil number and the concentrations of NE-alpha1-PI complex and IL-8 at baseline did not correlate with the reversibility and were not affected by treatment.
CONCLUSIONS: These findings suggest that the eosinophilic inflammation, not neutrophilic inflammation, in the airway is involved in the reversible part of the airflow obstruction in response to glucocorticoids in patients with pulmonary emphysema.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10084478     DOI: 10.1378/chest.115.3.697

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  28 in total

Review 1.  Inhaled and systemic corticosteroids in chronic obstructive pulmonary disease.

Authors:  Jeremy A Falk; Omar A Minai; Zab Mosenifar
Journal:  Proc Am Thorac Soc       Date:  2008-05-01

Review 2.  Benefits and risks of inhaled corticosteroids in chronic obstructive pulmonary disease.

Authors:  Marcel Bonay; Catherine Bancal; Bruno Crestani
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 3.  Inflammatory cells in the airways in COPD.

Authors:  R O'Donnell; D Breen; S Wilson; R Djukanovic
Journal:  Thorax       Date:  2006-05       Impact factor: 9.139

4.  Inhaled fluticasone and salmeterol suppress eosinophilic airway inflammation in chronic obstructive pulmonary disease: relations with lung function and bronchodilator reversibility.

Authors:  Diahn-Warng Perng; Cheng-Che Wu; Kang-Cheng Su; Yu-Chin Lee; Reury-Perng Perng; Chi-Wei Tao
Journal:  Lung       Date:  2006 Jul-Aug       Impact factor: 2.584

5.  Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD.

Authors:  Diana C Grootendorst; Stefanie A Gauw; Renate M Verhoosel; Peter J Sterk; Jeannette J Hospers; Dirk Bredenbröker; Thomas D Bethke; Pieter S Hiemstra; Klaus F Rabe
Journal:  Thorax       Date:  2007-06-15       Impact factor: 9.139

Review 6.  Pharmacological Management of Elderly Patients with Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome: Room for Speculation?

Authors:  Daniela Castiglia; Salvatore Battaglia; Alida Benfante; Claudio Sorino; Nicola Scichilone
Journal:  Drugs Aging       Date:  2016-06       Impact factor: 3.923

7.  Predicting sputum eosinophilia in exacerbations of COPD using exhaled nitric oxide.

Authors:  Szabolcs Soter; Imre Barta; Balazs Antus
Journal:  Inflammation       Date:  2013-10       Impact factor: 4.092

Review 8.  Chronic obstructive pulmonary disease . 6: The aetiology of exacerbations of chronic obstructive pulmonary disease.

Authors:  A J White; S Gompertz; R A Stockley
Journal:  Thorax       Date:  2003-01       Impact factor: 9.139

9.  Increased human Ca²⁺-activated Cl⁻ channel 1 expression and mucus overproduction in airway epithelia of smokers and chronic obstructive pulmonary disease patients.

Authors:  Hiroki Iwashita; Keisaku Fujimoto; Shigeru Morita; Atsushi Nakanishi; Keishi Kubo
Journal:  Respir Res       Date:  2012-06-25

10.  Specific IgA and metalloproteinase activity in bronchial secretions from stable chronic obstructive pulmonary disease patients colonized by Haemophilus influenzae.

Authors:  Laura Millares; Alicia Marin; Judith Garcia-Aymerich; Jaume Sauleda; José Belda; Eduard Monsó
Journal:  Respir Res       Date:  2012-12-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.